Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05107674 · ClinicalTrials.gov registry record · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
A Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Nurix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 345
- Enrollment target
- 17
- Study locations
NCT05107674 is a Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 345 participants, roughly in line with the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target. The trial reports 17 study locations across 10 states.
The verdict
NCT05107674, a Phase 1 study of Gastric Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Nurix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 345 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG NX-1607
Study Locations (17)
Other
- Addenbrookes Cambridge University Hospital - Cambridge
- Beatson West of Scotland Cancer Centre - Glasgow
- Sarah Cannon Research Institute - London
- The Christie NHS Foundation Trust - Manchester
- Northern Centre for Cancer Care - Newcastle
- Churchill Hospital - Oxford
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
- University of California, San Francisco - San Francisco
Colorado
- University of Colorado School of Medicine - Aurora
Illinois
- University of Chicago - Chicago
North Carolina
- University of North Carolina - Chapel Hill
Oklahoma
- University of Oklahoma - Oklahoma City
Texas
- MD Anderson Cancer Center - Houston
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107674
The ClinicalTrials.gov registry entry for NCT05107674 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target. The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT05107674 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05107674 about?
NCT05107674 is a clinical study titled "A Study of NX-1607 in Adults With Advanced Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
What is the current status of trial NCT05107674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 345 participants. The study started on 2021-09-29. Estimated completion is 2028-02-28.
What conditions does trial NCT05107674 study?
This clinical trial studies the following conditions: Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Urothelial Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT05107674?
The interventions under investigation include: Paclitaxel (DRUG), NX-1607 (DRUG).
Who is sponsoring clinical trial NCT05107674?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05107674 being conducted?
This trial has 17 study locations across California, Colorado, Illinois, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.